EA200600272A1 - Способ применения дапсона в качестве нейропротектора при церебральном инфаркте - Google Patents

Способ применения дапсона в качестве нейропротектора при церебральном инфаркте

Info

Publication number
EA200600272A1
EA200600272A1 EA200600272A EA200600272A EA200600272A1 EA 200600272 A1 EA200600272 A1 EA 200600272A1 EA 200600272 A EA200600272 A EA 200600272A EA 200600272 A EA200600272 A EA 200600272A EA 200600272 A1 EA200600272 A1 EA 200600272A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dapsone
neuroprotector
dapson
application
cerebral infarct
Prior art date
Application number
EA200600272A
Other languages
English (en)
Other versions
EA012174B1 (ru
Inventor
Кастаньеда Луис Камильо Риос
Марина Альтаграсия Мартинес
Хуан Надер Кавачи
Хайме Кравцов Хинич
Original Assignee
Столичный Автономный Университет
Национальный Институт Неврологии И Нейрохирургии Им. Мануэля Веласко Суареса
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Столичный Автономный Университет, Национальный Институт Неврологии И Нейрохирургии Им. Мануэля Веласко Суареса filed Critical Столичный Автономный Университет
Publication of EA200600272A1 publication Critical patent/EA200600272A1/ru
Publication of EA012174B1 publication Critical patent/EA012174B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Mobile Radio Communication Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Изобретение описывает способ применения дапсона как высокоэффективного лекарственного средства против тяжелых последствий церебрального инфаркта, приводящих к недееспособности пациентов. Дапсон анализируется в роли нейропротектора в модели церебрального инфаркта, вызванного окклюзией средней мозговой артерии у крыс и людей, страдающих острым церебральным инфарктом при наличии тромбоэмболии. В обоих типах исследований было продемонстрировано, что применение дапсона позволяет соответственно на 70 и 90% снизить тяжелые последствия ишемической атаки.
EA200600272A 2003-07-22 2004-03-16 Применение дапсона в качестве нейропротектора при остром церебральном инфаркте EA012174B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MXPA03006549A MXPA03006549A (es) 2003-07-22 2003-07-22 Uso de la dapsona como neuroprotector en el infarto cerebral.
PCT/MX2004/000018 WO2005007239A1 (es) 2003-07-22 2004-03-16 Uso de la dapsona como neuroprotector en el infarto cerebral

Publications (2)

Publication Number Publication Date
EA200600272A1 true EA200600272A1 (ru) 2006-10-27
EA012174B1 EA012174B1 (ru) 2009-08-28

Family

ID=34075071

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600272A EA012174B1 (ru) 2003-07-22 2004-03-16 Применение дапсона в качестве нейропротектора при остром церебральном инфаркте

Country Status (15)

Country Link
US (1) US8268893B2 (ru)
EP (1) EP1655055B1 (ru)
JP (1) JP5452844B2 (ru)
CN (1) CN100500246C (ru)
AT (1) ATE362783T1 (ru)
BR (1) BRPI0412212A (ru)
CA (1) CA2533181C (ru)
DE (1) DE602004006633T2 (ru)
EA (1) EA012174B1 (ru)
EC (1) ECSP066316A (ru)
ES (1) ES2287713T3 (ru)
HK (1) HK1098086A1 (ru)
MX (1) MXPA03006549A (ru)
PT (1) PT1655055E (ru)
WO (1) WO2005007239A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009004635A (es) * 2009-04-29 2010-10-29 Univ Autonoma Metropolitana Formas farmaceúticas solubles de la n,n´-diamino-difenilsulfona para su uso óptimo en el tratamiento de diversas enfermedades.
KR101875705B1 (ko) 2011-12-07 2018-07-06 삼성전자주식회사 디아미노디페닐술폰을 포함하는 근육 소모 관련 질환의 예방 또는 치료용 약학적 조성물
CN104177610A (zh) * 2013-05-27 2014-12-03 韩文毅 一种非线性的聚合物及其制备和用途
CN104177611A (zh) * 2013-05-27 2014-12-03 韩文毅 一种非线性的聚合物及其制备和用途
CN104069091A (zh) * 2014-07-09 2014-10-01 崔德华 氨苯砜在保护血脑屏障完整性中的应用
KR20160047318A (ko) * 2014-10-22 2016-05-02 삼성전자주식회사 다프손을 포함하는, 개체의 부위에서 혈관신생을 자극시키기 위한 조성물 및 그의 용도
KR20200107899A (ko) * 2019-11-16 2020-09-16 이종훈 알츠하이머병 혹은 뇌졸중의 뉴로인플라마섬의 치료제로서 디디에스 혹은 그 유도체

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532219A (en) * 1991-04-23 1996-07-02 The University Of British Columbia Dapsone and promin for the treatment of dementia
EE200100027A (et) * 1998-07-15 2002-06-17 Jomaa Hassan Fosfororgaanilised ühendid, neid sisaldav farmatseutiline preparaat ja nende kasutamine
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease

Also Published As

Publication number Publication date
CA2533181A1 (en) 2005-01-27
EP1655055B1 (en) 2007-05-23
CN100500246C (zh) 2009-06-17
ATE362783T1 (de) 2007-06-15
CA2533181C (en) 2012-08-07
MXPA03006549A (es) 2004-03-18
JP5452844B2 (ja) 2014-03-26
CN1852749A (zh) 2006-10-25
WO2005007239B1 (es) 2005-05-06
EA012174B1 (ru) 2009-08-28
DE602004006633D1 (de) 2007-07-05
ES2287713T3 (es) 2007-12-16
DE602004006633T2 (de) 2008-01-31
BRPI0412212A (pt) 2006-08-22
HK1098086A1 (en) 2007-07-13
JP2006528175A (ja) 2006-12-14
PT1655055E (pt) 2007-08-31
US8268893B2 (en) 2012-09-18
WO2005007239A1 (es) 2005-01-27
US20100063159A1 (en) 2010-03-11
ECSP066316A (es) 2006-10-25
EP1655055A1 (en) 2006-05-10

Similar Documents

Publication Publication Date Title
HK1098086A1 (en) Use of dapsone as a neuroprotector in preparing medicament for brain stroke
HRP20020593B1 (en) Brain, spinal and nerve injury treatment
ATE355293T1 (de) Substituierte 7-aza-(2.2.1)bicycloheptane für die behandlung von krankheiten
WO2004014352A3 (en) Methods for treating carbonic anhydrase mediated disorders
BRPI0506305A (pt) artigos e métodos de tratamento da pele
BR9814923A (pt) Método para tratamento de doença de alzheimer
DK1608350T3 (da) Fremgangsm der til forebyggelse, behandling og diagnosticering af lidelser af proteinaggregation
WO2007103380A3 (en) Monitoring and quantification of smoking behaviors
ATE311226T1 (de) Die glycin-betain für seine antithrombotische verwendung
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2001058476A3 (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
PL1979521T3 (pl) Nowy sposób impregnowania powierzchni tekstylnych
PL1744736T3 (pl) Sposób leczenia zespołu suchego oka i zapalenia błony naczyniowej oka
WO2006012521A3 (en) Treatment for ocular disease
ATE375339T1 (de) Verfahren zur herstellung von 1,3-dihydro-2h-3- benzazepin-2-on und anwendung zur herstellung von ivabradine und ihren pharmazeutischen annehmbaren salzen
WO2005034857A8 (en) Methods and compositions comprising diamines as new anti-tubercular therapeutics
WO2007047323A3 (en) Methods to treat alzheimer's disease or other disorders mediated by amyloid-beta accumulation in a subject
ATE345135T1 (de) Tropan-derivate mit dopamin-wiederaufnahme-hemmer-wirkung für die behandlung von ischämischen erkrankungen
WO2005047278A3 (de) Substituierte dihydrochinazoline ii
WO2007117272A3 (en) Methods for treatment of hemorrhagic shock and related disorders
WO2004058154A3 (en) Method of identifying therapeutic agents
RU2001128098A (ru) Способ лечения эпилепсии
WO2009049914A3 (en) Novel patient subgroups for thrombolysis
WO2024073125A3 (en) Deuterated hinokitiol derivatives
RU2001112324A (ru) Способ сквозной пластики нижнего века

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KZ TJ RU